Coya Therapeutics, Inc. (NASDAQ:COYA) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have been assigned an average recommendation of “Moderate Buy” from the seven analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $15.33.

A number of equities analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Thursday, October 15th. Roth Capital restated a “buy” rating and issued a $12.00 target price on shares of Coya Therapeutics in a report on Monday, August 24th. HC Wainwright reaffirmed a “buy” rating on shares of Coya Therapeutics in a research note on Friday, September 25th. BTIG Research reiterated a “buy” rating and set a $16.00 price target on shares of Coya Therapeutics in a report on Tuesday, September 15th. Finally, Chardan Capital reissued a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Wednesday, August 12th.

Coya Therapeutics Price Performance

COYA opened at $3.11 on Wednesday. The company’s 50 day simple moving average is $4.54 and its two-hundred day simple moving average is $4.63. Coya Therapeutics has a 1-year low of $3.03 and a 1-year high of $6.62. The firm has a market capitalization of $72.96 million, a price-to-earnings ratio of -2.91 and a beta of 0.70.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.07. The business had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.13 million. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%. On average, equities analysts anticipate that Coya Therapeutics will post -1.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC grew its stake in shares of Coya Therapeutics by 55.4% in the 1st quarter. Renaissance Technologies LLC now owns 103,964 shares of the company’s stock valued at $410,000 after buying an additional 37,064 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Coya Therapeutics by 205.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 95,919 shares of the company’s stock worth $377,000 after buying an additional 64,490 shares during the last quarter. Long Corridor Asset Management Ltd acquired a new stake in shares of Coya Therapeutics during the 2nd quarter worth approximately $227,000. ADAR1 Capital Management LLC purchased a new stake in shares of Coya Therapeutics during the 1st quarter valued at approximately $161,000. Finally, Cetera Investment Advisers raised its position in shares of Coya Therapeutics by 36.4% during the 1st quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock valued at $118,000 after buying an additional 8,000 shares during the period. 39.75% of the stock is owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune activity, and the company is studying their potential to address neurodegenerative diseases and other conditions involving inflammation and immune dysfunction.

The company’s lead investigational program, COYA 101, is an autologous Treg cell therapy being evaluated for amyotrophic lateral sclerosis (ALS). The treatment is designed to use a patient’s own regulatory T cells, which are expanded and functionally enhanced outside the body before being administered.